Marlin Equity Partners has acquired Datafarm, a Marlborough, Mass.-based provider of software that supports the regulatory business processes of life sciences companies. No financial terms were disclosed. Datafarm will be merged with Liquent Inc., a company Marlin acquired late last year from Thomson Reuters.
Liquent, Inc. (“Liquent”) is pleased to announce that Marlin Equity Partners (“Marlin”) has acquired Datafarm, Inc., a leading provider of software and services solutions designed to support the regulatory business processes of life sciences companies. In December 2009, Marlin acquired Liquent from Thomson Reuters. Datafarm will be fully merged into Liquent.
Shy Kumar, Datafarm’s founder and Chief Executive Officer, will join the Liquent executive team as Senior Vice President and Chief Technology Officer (CTO) and will report to Rick Riegel, Liquent CEO.
The combined portfolio of software offerings is strengthened with the addition of Datafarm’s S-Cubed, Web Viewer and Desktop Application. Datafarm’s UK and India subsidiaries will also become part of Liquent. In addition to providing Liquent with additional technical ability and depth, Liquent’s regulatory and clinical outsourcing services capability is strengthened by more than doubling the number of associates on the team, and with the addition of Datafarm India provides a proven low-cost, off shore capability to complement Liquent’s current on shore outsourcing services offerings.
“We are very excited to bring Datafarm and Liquent together into a single team. As a combined organization, we now have the deepest and broadest capability to service the industry,” commented Rick Riegel. “I am very excited to have Shy Kumar join our team as well. He is a well-known industry thought leader and innovator and I look forward to working closely with him to drive Liquent forward into the future.”
“The life sciences industries are converging as they seek to control costs while accelerating the drug development process world-wide,” Shy Kumar said. “Over the past twelve years, Datafarm’s software and services solutions have been successfully used by hundreds of life sciences companies to accelerate the regulatory approval process. This merger is consistent with Datafarm’s commitment and strategy to further enhance and expand the availability of global regulatory submission and outsourcing services solutions to the life sciences industry. We look forward to combining our outstanding technology and complementary wealth of experience with Liquent.”
“Marlin continues to recognize the life sciences industry’s constant challenge with regulatory change, drive for new product approvals, and mounting cost pressures. With the acquisition of Datafarm, we are continuing our investment in Liquent to support their evolving strategy to solve the industry’s complex regulatory challenges,” stated Jim Brady, Group President, Healthcare at Marlin Equity Partners.
About Liquent, Inc. 101 Gibraltar Road, Suite 200 • Horsham, PA 19044 Tel: 215-328-4300 www.liquent.com
Liquent regulatory solutions provide software and related regulatory and clinical services for the life sciences industry. These solutions and services help ensure clients meet the strict standards of regulatory authorities across the world helping them achieve quality, accuracy, and data integrity to deliver regulatory reports and submissions reliably and on time.
As a result, global life sciences companies, small tier to large tier, rely on Liquent regulatory solutions to provide the technology and services to compress the regulatory submissions and approval process, improving speed to market, cost control, and productivity, all of which contribute to ensuring patients’ and physicians’ timely access to new drugs. Over the last decade, thousands of regulatory submissions have been produced using Liquent world-class products and expert services. For more information please visit, www.liquent.com.
About Marlin Equity Partners
Marlin Equity Partners is a Los Angeles, California-based private investment firm with over $1 billion of capital under management. The firm is focused on providing corporate parents, shareholders and other stakeholders with tailored solutions that meet their business and liquidity needs in special situations. Marlin invests in businesses across multiple industries that are in the process of undergoing varying degrees of operational, financial or market-driven change where its capital base, industry relationships and extensive network of operational resources significantly strengthens a company’s outlook and enhances value. Since its inception, Marlin, through its group of funds and related companies, has successfully completed over 30 acquisitions. For more information, please visit www.marlinequity.com.